このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Vicore Pharma Holding マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Ahmed Mousa

最高経営責任者

kr6.3m

報酬総額

CEO給与比率	23.5%
CEO在任期間	1.4yrs
CEOの所有権	n/a
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Feb 10

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Sep 21

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

May 25

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Jan 10

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Nov 13

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Jul 26

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Mar 03

What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

Jan 11

CEO報酬分析

Vicore Pharma Holding の収益と比較して、Ahmed Mousa の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-kr213m
Dec 31 2023	kr6m	kr1m	-kr311m

報酬と市場: Ahmedの総報酬 ($USD 609.44K ) は、 Swedish市場 ($USD 481.25K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Ahmedの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Ahmed Mousa (39 yo)

1.4yrs

在職期間

kr6,339,074

報酬

Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ahmed Mousa	Chief Executive Officer	1.4yrs	kr6.34m	データなし
Hans Jeppsson	Chief Financial Officer	7yrs	データなし	0.0045% SEK 108.9k
Mikael Nygård	Vice President of Operations & Corporate Strategy	less than a year	データなし	0.0036% SEK 87.9k
Johan Raud	Chief Scientific Officer	6.4yrs	データなし	0.21% SEK 5.2m
Nina Carlen	Chief Administrative Officer	15.4yrs	データなし	0.022% SEK 533.7k
Jessica Shull	Head of Digital Therapeutics & Director of Digital Health	3.1yrs	データなし	データなし
Asa Magnusson	Chief Engagement & Commercial Officer	2.7yrs	データなし	データなし
Bertil Lindmark	Chief Medical Officer	less than a year	データなし	データなし
Sophie Bertilsson	Interim Head of CMC	less than a year	データなし	データなし
Jimmie Hofman	Vice President of Business Development	less than a year	データなし	データなし

2.0yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: VICOの経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jacob Gunterberg	Director	no data	kr886.00k	0.0057% SEK 139.6k
Michael Buschle	Director	1.1yrs	kr405.00k	データなし
Ann Barbier	Director	less than a year	データなし	データなし
Yasir Al-Wakeel	Director	less than a year	データなし	データなし
Hans J. G. C. Schikan	Independent Chairman	5.8yrs	kr450.00k	0.0036% SEK 87.2k
Elisabeth Bjork	Director	1.1yrs	kr405.00k	データなし
Heidi Hunter	Independent Director	4.1yrs	kr519.00k	0.0045% SEK 108.9k

1.1yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: VICOの取締役会は経験豊富ではない ( 1.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Vicore Pharma Holding マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Less than half of directors are independent

Vicore Pharma Holding AB (Publ) Announces Board Appointments

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (Publ) Announces Executive Changes

Recent updates

New minor risk - Share price stability

Less than half of directors are independent

Consensus EPS estimates fall by 20%

Vicore Pharma Holding AB (Publ) Announces Board Appointments

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Vicore Pharma Holding AB (Publ) Announces Maarten Kraan, as Board Member Declined Re-Election

Price target decreased by 13% to kr61.50

Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis

Consensus revenue estimates increase by 3,123,023%

No longer forecast to breakeven

Vicore Pharma Holding AB (publ) to Report Q4, 2024 Results on Feb 27, 2025

Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans

Vicore Pharma Holding AB (publ) Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates

Vicore Pharma Holding AB (publ) Appoints Bertil Lindmark as Chief Medical Officer

Vicore Pharma Holding AB (publ) to Report Q2, 2024 Results on Aug 22, 2024

Vicore Pharma Holding AB (publ), Annual General Meeting, May 07, 2024

Vicore Pharma Holding AB (publ) Provides Update Regarding Phase 1 Study of C106

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

Vicore Pharma Holding AB (publ) Reports Data from EndoPAT® Exploratory Trial

New major risk - Shareholder dilution

Vicore Pharma Holding AB (Publ) Announces Executive Changes

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

Vicore Pharma Holding AB (publ) Reports New 36-Week Data from the Air Trial Demonstrating Sustainable Disease Stimulating the Potential of A New Class of Drugs to Stop Disease Propose and Restate in IPF Patients

Price target decreased to kr74.67

Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)

Now 20% undervalued after recent price drop

Vicore Pharma Holding AB (publ) to Report Q2, 2023 Results on Aug 24, 2023

Vicore Pharma Holding AB (publ) Announces First Patient Enrolled in COMPANION; a Digital Therapeutic Pivotal Study for Patients with Pulmonary Fibrosis

Consensus forecasts updated

Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?

Vicore Pharma Holding AB (publ) Announces New Data from the IPF Air Trial Further Strengthening the Benefit-Risk Profile of C21

Vicore Pharma Holding AB (publ) Announces the Appointment of Nomination Committee

Consensus forecasts updated

Vicore Selects New ATRAG as Next Drug Candidate

Vicore Pharma Holding AB (publ) Announces Positive Results for the Pilot Phase of the COMPANION study

Vicore Pharma Holding AB Announces C21 Promotes Vascular Function in Humans

Price target decreased to kr80.40

Vicore Pharma Holding AB (Publ) Provides an Update on the Attract-3 Covid-19 Trial

Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation

Vicore Pharma Holding AB (publ) Announces Initiation of First-In-Human Trial with the Novel ATRAG C106

Independent Director recently bought kr87k worth of stock

Vicore Pharma Holding AB (publ) Amends Primary Endpoint to Accelerate the Phase 3 Trial in COVID-19 Patients

Price target increased to kr93.50

Vicore Launches COMPANION, A Clinical Study Investigating the Benefit of Digital Therapy on Anxiety in Patients with Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (Publ) Announces Plans to Initiate A Clinical Trial with C21 in PAH

Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?

Vicore Pharma Holding AB (Publ) Announces Advancing its First New Chemical Entity from the VP03 Program to a First in Human Phase 1 Trial

Vicore Pharma Holding Announces Data from an Interim Analysis of the Phase 2 Proof-of-Concept Study in IPF

Price target decreased to kr55.00

Vicore Pharma Holding AB (publ) Starts Dosing of First Covid-19 Patients in the Global Phase 3 Trial ATTRACT-3

No longer forecast to breakeven

High number of new directors

Vicore Pharma Holding AB (publ) Announces FDA Acceptance for Pivotal Phase 3 Trial of C21 in COVID-19

Price target increased to kr72.00

Vicore Pharma Holding AB (Publ) Announces Top Line Data from A Phase Ii Study of Its Oral Angiotensin II Type 2 Receptor (AT2R) Agonist C21 in Patients with Systemic Sclerosis and Raynaud's Phenomenon

Vicore Pharma Holding AB (Publ) Resumes VP02 Production

Vicore Pharma Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 336 million.

Vicore Pharma Holding AB Announces Positive Data from Phase II Study Attract in Patients with Covid-19 Published Online

What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition

New 90-day high: kr28.70

Price target raised to kr54.00

Vicore Pharma Holding Reports an Expanded Data Analysis to Follow Up the Encouraging Top Line Data from the ATTRACT

Vicore Pharma Holding AB (Publ) Announces Last Patient Last Visit in the Mechanistic Phase II Study with C21 in Systemic Sclerosis

Vicore Pharma Reports Positive Top Line Data from the ATTRACT clinical study in patients with COVID-19

New 90-day low: kr18.40

Vicore Pharma Holding AB Recruits the First Patient in the Phase II Proof-Of-Concept Study in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 15, 2021

マネジメント基準チェック /24